AI assistant
Apellis Pharmaceuticals, Inc. — Director's Dealing 2017
Nov 8, 2017
31417_dirs_2017-11-08_061aaa95-f6b7-48a1-8fe5-3a8503948088.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-08
Reporting Person: Machiels Alec (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 381325 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.67 | 2023-12-04 | Common Stock (187529) | Direct | |
| Stock Option (right to buy) | $14.00 | 2027-11-08 | Common Stock (121894) | Direct |
Footnotes
F1: This option was granted on December 5, 2013 and has vested as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.
F2: This option was granted on November 8, 2017 and immediately vested as to 50% of the shares underlying the option on November 8, 2017, with the remainder vesting in 12 equal monthly installments with the first installment vesting on December 8, 2017.